Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
e-Therapeutics proposes £29m fundraising, delisting from AIM
(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday. The AIM-traded firm said it was planning to raise £28.9m through a subscription for 192,666,667 new shares at a price of 15p each.
It said the subscription would be led by funds managed by M&G Investment Management, and Richard Griffiths and his controlled undertakings, both existing shareholders of the company.
The move was aimed at fortifying the company's balance sheet, considering its current cash position of £18m.
e-Therapeutics also proposed the cancellation of the admission of its shares to trading on AIM - a decision which it said aligned with its broader strategy to explore listing on Nasdaq in the future.
Both the subscription and the cancellation were subject to shareholder approval, which would be sought at a general meeting scheduled for 29 April.
The company said it had already secured irrevocable undertakings from the subscribers, representing 46.68% of its existing shares, to vote in favour of the proposed resolutions.
Its directors had also expressed their intention to vote their entire holdings in favour of the resolutions, amounting to interests in 52,735,562 shares, or around 9% of its existing shares.
"We decided to remain on the AIM market and embarked on a capital raise roadshow in February to March," said chief executive officer Ali Mortazavi.
"Despite the firm commitments given by our two largest shareholders, the Board was extremely disappointed by the lack of institutional UK interest in our innovative, technology-driven value propositions.
"ETX struggled to get sufficient engagement from the vast majority of the institutions who were approached, reflecting the risk appetite of the UK markets."
Mortazavi said the board believed the current valuation did not reflect ETX's position as a "leading TechBio company".
He said the firm had powerful enabling technologies and a pipeline of differentiated RNAi assets, but added that there was a "limited audience" on AIM for such companies.
"We are of the firm belief that it is in the best interest of all shareholders to delist from the AIM market, with a strong cash position of approximately £47 million following this fundraise.
"We have also stated our willingness to explore relisting the company in the future on the US Nasdaq exchange where the large gap in the valuation of ETX compared to its US peers can hopefully be narrowed."
At 1243 BST, shares in e-Therapeutics were down 8% at 11.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.